Printer Friendly 4,479,661 articles and books

Periodicals Literature Keyword Title Author Topic

Member login User name    Password    Remember me Join us Forgot password?

Submit articles free

Browse HIV (Viruses) topic

Drug therapy subtopic

Articles 1-100 out of 100 article(s) Title Author Type Date Words Stanford Study Finds HIV Drug Can Persist in Mothers' Milk, Increasing Risk to Them and Their Babies. Aug 5, 2008 925 Argos Therapeutics' Arcelis(TM) Personalized Immunotherapy Platform in HIV Achieves Primary Endpoint in Phase 1 Trial. Aug 5, 2008 690 Great strides made in universal access to HIV/AIDS treatments. Kohlway, Elizabeth Aug 1, 2008 686 Gilead Initiates Phase III Clinical Trial of Elvitegravir, an Investigational Integrase Inhibitor for HIV. Jul 22, 2008 962 FDA Approves Energex Systems, Inc. Non-Drug Therapy For HIV Research. Jul 14, 2008 652 Samaritan's HIV Drug Granted IND from FDA. Clinical report Jul 8, 2008 550 Aethlon Medical Announces Second HIV/AIDS Treatment Site. Jul 1, 2008 626 Aethlon Medical Announces "First-In-Man" HIV/AIDS Treatment Study. Jun 24, 2008 869 Panacos Presents Bevirimat Patient Response Predictors at the International HIV Drug Resistance Workshop. Clinical report Jun 11, 2008 1256 Argos Therapeutics Initiates Phase 2 Proof-of-Concept Trial for its Arcelis(TM) Personalized Immunotherapy Platform in HIV. May 12, 2008 570 Virostatics Doses First Patient in Phase IIa Trial of VS411 for the Treatment of HIV Infection. Clinical report May 12, 2008 633 NanoViricides Commences HIV Drug Animal Trials. Apr 7, 2008 510 Ardea HIV drug meets study goals. Chambers, Heather Brief article Mar 24, 2008 240 American Academy of HIV Medicine Streamlines Delivery of Critical News and Information to Its Members and HIV Specialists Through ActiveAccess Desktop Application. Mar 18, 2008 482 Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials. Mar 1, 2008 608 Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts. Mar 1, 2008 516 Argos Therapeutics Publishes Novel Approach to Amplifying HIV Genes for Personalized Immunotherapy Treatments for HIV. Clinical report Jan 30, 2008 542 European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection. Dec 17, 2007 2219 Canopus BioPharma Selected to Present its Drug Candidate for HIV/AIDS Treatment at the Global Summit on AIDS and the Church. Dec 3, 2007 1077 Obstacles to effective treatment for HIV and Aids. Williams, Kari Report Dec 1, 2007 1045 Data from STEP Study Presented at Open Scientific Session Confirm Merck's Investigational HIV Vaccine was not Effective. Nov 7, 2007 3273 Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV. Oct 17, 2007 2168 UPDATE: FDA Approves ISENTRESS(TM) (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor. Oct 15, 2007 9780 UPDATE: FDA Approves ISENTRESS(TM) (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor. Oct 12, 2007 9768 Novel Antiviral HIV Drug SpirH(TM) Offers New Hope for AIDS Patients Worldwide. Oct 9, 2007 903 Pfizer's Celsentri(R) Approved in the European Union, Providing a Novel Treatment Option for Treatment-Experienced HIV Patients. Sep 24, 2007 624 Data Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Demonstrate That INCB9471 is a Potent, Selective Inhibitor of the HIV-1 Virus with Excellent Pharmacokinetics Suitable for Once-Daily Dosing. Conference news Sep 18, 2007 882 Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug Selzentry(TM) (Maraviroc). Sep 18, 2007 843 FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS(TM) (raltegravir), Merck's Investigational Oral Integrase Inhibitor, for Treatment of HIV. Sep 5, 2007 757 Examine Detailed Information on the Current Drug Pipeline for AIDS and HIV. Aug 23, 2007 356 Entry of New Drug Classes Redefining the HIV Market. Aug 8, 2007 228 Pfizer's SelzentryTM (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA. Aug 6, 2007 1001 HIV Report Gives Detailed Analysis of the Antiretroviral Therapy Market. Jul 23, 2007 362 Rising prevalence of variant HIV-1 subtypes poses new diagnostic challenge. Robinson, John, M. Jul 1, 2007 972 FDA Priority Review Granted for ISENTRESS(TM) (raltegravir), Merck's Investigational Integrase Inhibitor for HIV. Jun 27, 2007 765 VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models. May 23, 2007 425 New drug for HIV patients. May 1, 2007 153 Tuberculosis drug resistance and HIV infection, the Netherlands. van Soolingen, Dick May 1, 2007 2590 FDA Advisory Committee Recommends Accelerated Approval of Pfizer's Maraviroc for Treatment-Experienced Patients Infected with CCR5-tropic HIV-1. Apr 24, 2007 424 Avexa Secures CCR5 Inhibitor HIV Program With TargetDrug. Apr 18, 2007 510 The next line of attack: the previous generation of anti-HIV drugs changed AIDS from an untreatable epidemic into a survivable disease. The next crop aims to get rid of the virus altogether. Kuhr, Fred Apr 10, 2007 840 Sensitive Pediatric Pharmacology Assays for HIV Drugs Developed by Vitalea Science. Feb 19, 2007 533 Personalized Immunotherapy Clinical Trial Initiated in HIV Patients with Argos Therapeutics' AGS-004. Feb 9, 2007 525 Bio-Bridge Science Dedicated to Developing a Vaccine to Fight HIV. Dec 1, 2006 404 New program will track HIV treatments and outcomes. Hollander, Dore Dec 1, 2006 165 GenVec HIV Vaccine Program to Receive Additional Funding. Oct 10, 2006 577 GenVec Announces New $52 Million Contract with NIH/NIAID Vaccine Research Center to Support HIV Vaccine Production. Oct 5, 2006 585 REPEAT/Viral Suppression in Triple-Class Drug Resistant Patients Maintained after 24 Weeks of Treatment with MK-0518, an Investigational HIV Integrase Inhibitor, Plus Optimized Background Therapy (OBT). Oct 2, 2006 1150 GENVAC VACCINE ENTERS HIV HUMAN THERAPEUTIC CLINICAL TRIALS. Oct 1, 2006 438 Viral Suppression in Triple-Class Drug Resistant Patients Maintained after 24 Weeks of Treatment with MK-0518, an Investigational HIV Integrase Inhibitor, Plus Optimized Background Therapy (OBT). Sep 29, 2006 1150 OraSure Technologies Commences Initial Studies for FDA Approval of Home Use Rapid HIV Test Kit. Sep 27, 2006 946 Interim Data from Targeted Genetics' Phase I HIV/AIDS Vaccine Trial to Be Presented at Leading European AIDS Vaccine Meeting; Vaccine Candidate Well Tolerated; Modest Immune Response Observed in a Subset of Patients. Aug 30, 2006 929 GenVec Vaccine Technology Enters First HIV Human Therapeutic Clinical Trials at Vaccine Research Center at NIH. Aug 22, 2006 714 Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients with Limited Available Treatment Options; Worldwide Access Program will be Conducted Along with Phase III Studies. Aug 17, 2006 1038 Panacos Presents Progress on HIV Fusion Inhibitor Program at International AIDS Conference. Aug 14, 2006 714 The Immune Response Corporation Receives Approval for Expansion of Phase II Trial in France for Investigative HIV Immunotherapy IR103. Aug 1, 2006 1046 The Immune Response Corporation Announces That Phase II Preliminary Data Indicate Investigative HIV Immunotherapy IR103 Enhances Immune Responses in Antiretroviral Naive HIV-Infected Patients. Jun 26, 2006 1292 U.S. FDA Approval of Boosted Protease Inhibitor Enables Potent New HIV Drug Combination with FUZEON(R). Jun 23, 2006 1531 Samaritan to Initiate Phase III Clinical Trial in Europe to Accelerate Development Timeline of Its HIV Oral Entry Inhibitor SP01A. Chronology Jun 15, 2006 549 Panacos Presents Data on Lack of Clinical Resistance Development to Bevirimat (PA-457) at International HIV Drug Resistance Conference. Jun 14, 2006 709 Incyte Begins Phase I Study of New HIV Drug in Healthy Volunteers. May 10, 2006 540 St. Mary's Medical Center Highlights National Health Issues for May; Eyes, Osteoporosis, Fitness, Emergency Room Services and HIV Vaccine Awareness Included in This Month's Health Focus. Apr 28, 2006 1041 Zambia Begins First Preventive HIV Vaccine Trial. Apr 26, 2006 1182 The Immune Response Corporation Announces New Business Strategy; Emphasizes Focus on Promising MS Treatment and Second Generation HIV Therapy. Feb 8, 2006 2054 Vanderbilt University, Brigham Young University, and Ceragenix Pharmaceuticals Report Novel Drug Compound Kills Multiple HIV Strains; Synthetic Small Molecule Acts Through Unique Strain-Independent Virucidal Mechanism. Feb 6, 2006 901 The Uganda Virus Research Institute (UVRI), in collaboration with the International AIDS Vaccine Initiative (IAVI) and Targeted Genetics, Launches HIV/AIDS Vaccine Trial in Entebbe, Uganda. Feb 6, 2006 1374 Bio-Bridge Science Inc. Reports Encouraging Data in Pre-Clinical Trials of HIV Vaccine. Feb 1, 2006 513 Study finds 3,000,000 years of life saved by HIV treatment in the U.S. Jan 1, 2006 103 CytoDyn Picks San Francisco for Next Trial. Nov 28, 2005 248 Targeted Genetics Named as Subcontractor to NIAID Contract to Expand AAV-Based HIV Vaccine Program; NIAID Funding to Total Approximately $22 Million. Nov 28, 2005 1292 Locus Announces Continuing AIDS Collaboration with Weill Cornell Medical College. Nov 15, 2005 670 IAVI Begins First Phase II Preventive HIV Vaccine Trial in South Africa to Test Targeted Genetics' HIV Vaccine Candidate. Nov 14, 2005 1118 Wyeth enters into $32 million contract with NIH for ongoing HIV vaccine tesearch. Nov 1, 2005 436 Survey Provides Insights Into Factors Influencing Drug Adherence Among HIV Patients. Oct 18, 2005 104 Nutra Pharma Announces ReceptoPharm Facilities Have Been GMP-Certified for Drug Production. Oct 12, 2005 782 Once-a-day pill falls short. Brief Article Oct 11, 2005 97 Vaccine Research Center (VRC) Initiates Phase II Testing of an HIV Vaccine Developed in Collaboration with GenVec. Oct 11, 2005 541 PhotoImmune Biotechnology Presents HIV Preventative Vaccine Methodology at Medtech Insight's ''Investment In Innovation'' Boston Conference. Oct 6, 2005 501 One-Day HIV treatment meeting near Boston, November 11. Sep 30, 2005 105 HIV treatment in resource-limited settings: call for information. James, John S. Sep 30, 2005 517 Superstrain not super. Brief Article Sep 13, 2005 112 Looking east for a new HIV drug. Brief Article Aug 30, 2005 91 Half the world's poor uses generic HIV drugs, U.S. urged to cooperate. Aug 22, 2005 209 One! Two pharmaceutical giants team up to find a simpler, better way to fight HIV. Adams, Bob Jun 21, 2005 399 Vaccine-Preventable Hepatitis (VPH) and high-risk patients with HIV. Advertisement Jun 1, 2005 1171 Lexiva: blood levels not lowered when taken simultaneously with Nexium. James, John S. May 27, 2005 501 Super strain of HIV? Apr 1, 2005 392 The price of Fuzeon resistance. Brief Article Apr 1, 2005 153 Dangers of treatment interruption. Brief Article Apr 1, 2005 92 Tipranavir. Apr 1, 2005 91 Update to HIV treatment guidelines. Brief Article Apr 1, 2005 274 Kaletra warning. Advertisement Apr 1, 2005 296 Studies in Galveston. Apr 1, 2005 466 Serving patients, not patents. Brief Article Oct 1, 2004 167 Kaletra monotherapy controversy: AmfAR publishes overview. Brief Article Sep 24, 2004 182 The hepatitis C drug development pipeline. Raymond, Daniel Sep 22, 2004 2442 Heart attack risks. Brief Article Jun 1, 2004 193 World's health. (Health). Brief Article Jul 14, 2003 248 Do HIV drugs affect men and women differently? Sex, Gender and Drug Side Effects. d'Adesky, Anne-Christine Mar 1, 2003 1537 Concerns about the pill. Mar 1, 2003 221

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles